Inclusion completed

Niraparib and/or Niraparib-bevacizumab combination against bevacizumab alone in Women with platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancer Part 1: AVANOVA1 and part 2: AVANOVA2

Cancer type: Ovarian cancer

Phase: I

Principal Investigator: Mirza Mansoor Raza

Country: DK

Keywords: Denmark, Rigshospitalet, PARP-inhibitor + bevacizumab,

Status: Inclusion completed

Link to